Brief: Briacell Reports Unprecedented Preliminary Survival And Clinical Benefit In Antibody-Drug Conjugate (Adc) Refractory Patient Subset
20/12/2023 13:42
Dec 20 (Reuters) - Briacell Therapeutics Corp BCT.TO :
* BRIACELL REPORTS UNPRECEDENTED PRELIMINARY SURVIVAL AND
CLINICAL
BENEFIT IN ANTIBODY-DRUG CONJUGATE (ADC) REFRACTORY PATIENT
SUBSET
* BRIACELL THERAPEUTICS CORP - DISEASE CONTROL RATE OF 40%
WAS
OBSERVED IN EVALUABLE PATIENTS FURTHER INDICATING CLINICAL
BENEFIT
* BRIACELL THERAPEUTICS CORP - PROGRESSION FREE SURVIVAL
(PFS) WAS
SIMILAR OR BETTER THAN LAST REGIMEN IN 40% OF PATIENTS
HIGHLIGHTING CLINICAL EFFICACY
* BRIACELL THERAPEUTICS CORP - IN SUBSET OF ADC REFRACTORY
PATIENTS, OS DATA OF BRIACELL'S COMBINATION REGIMEN EXCEEDED
THAT OF SIMILAR STUDIES
Source text for Eikon: ID:nGNX7jQSPT
Further company coverage: BCT.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Briacell Therapeutics
See all newsBrief: Briacell Therapeutics Prices 1.45 Million Common Shares At $3.25 Per Share
Brief: Briacell Receives Positive Recommendation From Data Safety Monitoring Board (Dsmb) For Phase 3 Study In Metastatic Breast Cancer
Brief: Briacell Expands Pipeline To Include An Ovarian Cancer Immunotherapy Candidate, Bria-Ova+™
Brief: Briacell Phase 3 Bria-Imt™ Study Enrollment Surpasses 230 Patients
Brief: Briacell Adds Nyu Langone Health’S Perlmutter Cancer Center As Clinical Site In Pivotal Phase 3 Breast Cancer Study